Clinical Trial Update: Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating CTAP101 for secondary hyperparathyroidism in CKD Stage 3-4 with vitamin D insufficiency has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism
• Vitamin Deficiency

Drugs mentioned

• CTAP101

Snippet

Sponsor: OPKO IP Holdings II, Inc. | Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary | Phase 3 | Status: COMPLETED | Results posted: 2016-08-17